2026-05-27T05:33:08Zhttps://riuma.uma.es/rest/oai/request

oai:riuma.uma.es:10630/446962026-02-03T11:30:46Zcom_10630_2254col_10630_37953

A multi-metabolite signature robustly predicts long-term mortality in the PREDIMED trial and several US cohorts Fernández-Duval, Gonzalo Razquin, Cristina Wang, Fenglei Yun, Huan Hu, Jie Guasch-Ferré, Marta Rexrode, Kathryn Balasubramanian, Raji García-Gavilán, Jesús F Ruiz-Canela, Miguel Clish, Clary B Corella, Dolores Gómez-Gracia, Enrique Fiol, Miquel Estruch, Ramón Lapetra, José Fito, Montse Serra-Majem, Luis Ros, Emilio Liang, Liming Dennis, Courtney Asensio, Eva M. Castañer, Olga Planes, Francisco J. Salas-Salvadó, Jordi Hu, Frank B. Toledo, Estefanía Martínez-González, Miguel A. Metabolitos Metabolome-based biomarkers contribute to identify mechanisms of disease and to a better understanding of overall mortality. In a long-term follow-up subsample (n = 1878) of the PREDIMED trial, among 337 candidate baseline plasma metabolites repeatedly assessed at baseline and after 1 year, 38 plasma metabolites were identified as predictors of all-cause mortality. Gamma-amino-butyric acid (GABA), homoarginine, serine, creatine, 1-methylnicotinamide and a set of sphingomyelins, plasmalogens, phosphatidylethanolamines and cholesterol esters were inversely associated with all-cause mortality, whereas plasma dimethylguanidino valeric acid (DMGV), choline, short and long-chain acylcarnitines, 4-acetamidobutanoate, pseudouridine, 7-methylguanine, N6-acetyllysine, phenylacetylglutamine and creatinine were associated with higher mortality. The multimetabolite signature created as a linear combination of these selected metabolites, also showed a strong association with all-cause mortality using plasma samples collected at 1-year follow-up in PREDIMED. This association was subsequently confirmed in 4 independent American cohorts, validating the signature as a consistent predictor of all-cause mortality across diverse populations. 2026-01-21T19:25:36Z 2025-09 journal article Fernández-Duval G, Razquin C, Wang F, Yun H, Hu J, Guasch-Ferré M, Rexrode K, Balasubramanian R, García-Gavilán J, Ruiz-Canela M, Clish CB, Corella D, Gómez-Gracia E, Fiol M, Estruch R, Lapetra J, Fitó M, Serra-Majem L, Ros E, Liang L, Dennis C, Asensio EM, Castañer O, Planes FJ, Salas-Salvadó J, Hu FB, Toledo E, Martínez-González MA. A multi-metabolite signature robustly predicts long-term mortality in the PREDIMED trial and several US cohorts. Metabolism. 2025 Sep;170:156195. doi: 10.1016/j.metabol.2025.156195. Epub 2025 Mar 17. PMID: 40107652; PMCID: PMC12245597. https://hdl.handle.net/10630/44696 10.1016/j.metabol.2025.156195 eng http://creativecommons.org/licenses/by-nc-nd/4.0/ open access Attribution-NonCommercial-NoDerivatives 4.0 International Elsevier